Developer docs
API playgroundTry for free, no card

Search company profiles

Variantyx

Full company profile

uuid0000l5d

Namestring
Variantyx
Legal namestring
Variantyx, Inc.
Websiteurl
variantyx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Variantyx is a private molecular diagnostics company founded in 2014 and headquartered in Framingham, Massachusetts, that provides clinical whole genome sequencing-based genetic testing for rare genetic disorders, reproductive genetics, precision oncology, neurology, and wellness applications. The company operates a proprietary PCR-free whole genome sequencing platform paired with its Genomic Intelligence analytical software, which detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions) from a single sample with reported sensitivity and specificity above 99.9%. Its product portfolio includes the comprehensive Genomic Unity 2.0 test (the only diagnostic combining short-read and long-read sequencing in one report), the Lightning 2.0 rapid genome line delivering results in 5 days or less for NICU/PICU/ICU patients, the OncoAlly hereditary cancer panels, the IriSight reproductive/prenatal testing line, and the Genomic Inform wellness offering, spanning more than 30 distinct SKUs.

Variantyx sells primarily to healthcare providers (geneticists, neurologists, oncologists, obstetricians) through a sales-led go-to-market combining field clinical sales specialists, a Provider Portal for online ordering, and a Clinical Coordination team for fax/phone orders, with mobile phlebotomy coordination and direct-to-patient kit shipping. Tests are billed through commercial insurance, Medicaid, institutional billing, or self-pay, with a Patient Assistance Program available for qualifying commercially insured patients. The company has raised over $125 million in cumulative private financing across multiple rounds since inception, including a $41.5M Series C-2 in February 2022 led by New Era Capital Partners and a $36M round in April 2024 with Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. Operations span North America and Europe, with the 2024 round explicitly funding further technological and commercial expansion as the market shifts from targeted panels and exomes toward whole genome testing.

Short descriptiontext

Variantyx is a private molecular diagnostics company operating a proprietary PCR-free whole genome sequencing platform with Genomic Intelligence software to deliver comprehensive clinical genetic testing for rare disorders, reproductive genetics, oncology, neurology, and wellness applications to healthcare providers across North America and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFramingham, United States
HQ citystring
Framingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genetic testing, whole genome sequencing, molecular diagnostics, rare disease diagnostics, hereditary cancer testing
Industry5 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Genetic Diagnostics Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Genetic Testing Services
TypeSubscription Recurring
Description

Variantyx provides genetic diagnostic testing services to healthcare providers and patients. The company accepts insurance (commercial and Medicaid) and institutional billing, as well as self-pay options. Financial assistance through a Patient Assistance Program is available for patients with commercial insurance meeting certain criteria.

variantyx.com
2Laboratory Testing
TypeOne Time License
Description

Clinical laboratory testing services billed through insurance or paid directly by patients/providers. Testing includes comprehensive genomic analyses for rare genetic disorders, reproductive genetics, precision oncology, and wellness.

variantyx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Insurance billing (commercial and Medicaid)
ModelOtherBilling cadencePay-as-you-go
Notes

Insurance billing accepted for commercial and Medicaid plans. Patient Assistance Program available for out-of-pocket costs when certain criteria are met.

variantyx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Genomic Unity
Description

Portfolio of tests for rare genetic disorders including whole genome, exome, and targeted analyses

variantyx.com
+5 more records
Core offering1 text field

Variantyx is a clinical molecular diagnostics laboratory providing comprehensive genetic testing services based on PCR-free whole genome sequencing. The company delivers a unified clinical report from a single sample that detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions, methylation patterns), replacing multiple traditional tests such as WES, CMA, MLPA, single-gene panels, and PCR/Southern blot. Test products are organized under the Genomic Unity, OncoAlly, IriSight, Lightning, and Genomic Inform brands and are ordered primarily by healthcare providers for rare disease diagnosis, reproductive genetics, hereditary cancer, and wellness applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 44% diagnostic yield in neonate cases (157 cases), increasing to 48% for classic NICU indications and 71% for select phenotypes
+2 more records
Product overview1 text field

Variantyx is a molecular diagnostics company offering a comprehensive portfolio of genetic testing products built on a proprietary whole genome sequencing (WGS) platform paired with Genomic Intelligence® analytical software. The product ecosystem is organized around two main brands: Genomic Unity® for rare genetic disorders, neurology, reproductive, and precision oncology testing, and OncoAlly® for hereditary cancer analysis. The flagship Genomic Unity® 2.0 combines short and long-read genome sequencing technologies. The comprehensive analysis products (Whole Genome, Exome Plus, Exome Analysis) form the core offering, while targeted analyses cover specific conditions (mitochondrial disorders, cardiomyopathy, ataxia, epilepsy, neuropathies, etc.). Rapid testing is available through the Lightning Genome Analysis line with results in 5 days or less. Reproductive genetics are served through the IriSight® brand for prenatal and pregnancy loss testing. Wellness testing is provided via Genomic Inform®.

Product and service7 records
1Genomic Unity® 2.0
CategoryRare Genetic Disorder Diagnostics
Description

The only whole genome-based diagnostic test that combines short and long-read sequencing technologies in one clinical report, identifying genetic variants that correlate with the patient's phenotype. It is the most comprehensive genomic test in the company's portfolio, designed for healthcare providers diagnosing patients with suspected genetic conditions.

2Genomic Unity® Whole Genome Analysis
CategoryRare Genetic Disorder Diagnostics
Description

Comprehensive diagnostic test using a whole genome platform to detect all major clinically relevant variant types from a single sample, replacing WES, CMA, MLPA, and single-gene testing. Ordered by geneticists and other specialists for patients with suspected rare genetic disorders.

3Genomic Unity® Exome Plus Analysis
CategoryRare Genetic Disorder Diagnostics
Description

Comprehensive diagnostic test using the whole genome platform to detect all major clinically relevant variant types from a single sample, analyzing patient DNA jointly with parental DNA when family samples are included. Used by geneticists and other specialists for rare disease diagnosis.

4Genomic Unity® Lightning Genome Analysis
CategoryRapid Inpatient Genetic Testing
Description

Rapid diagnostic test for acutely ill individuals in NICU, PICU, or ICU settings, providing a comprehensive diagnostic report in 5 days or less using short-read genome sequencing. Lightning 2.0 variants combine short and long-read sequencing with 27-44 repeat expansion gene analysis and methylation analysis for variant phasing.

5OncoAlly® Comprehensive Hereditary Cancer Analysis
CategoryPrecision Oncology / Hereditary Cancer
Description

Targeted test focusing on 117 genes associated with hereditary cancer, sequencing and analyzing the entire gene for comprehensive variant detection. Used by oncologists and genetic counselors to assess hereditary cancer risk in patients.

6IriSight® Comprehensive Prenatal Analysis
CategoryReproductive Genetics
Description

Comprehensive prenatal diagnostic test using the whole genome platform for fetal DNA analysis jointly with parental DNA, replacing WES, CMA, MLPA, and single-gene testing. Ordered by obstetricians, maternal-fetal medicine specialists, and geneticists for pregnancies at elevated risk.

7Genomic Inform® Wellness Testing
CategoryWellness / Predictive Genetic Screening
Description

Wellness predictive screening test providing information about risks across multiple health areas including cancer, neurological disorders, metabolic disorders, heart conditions, and carrier status. Aimed at healthy adults seeking predictive genetic insights.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GeneDx (a subsidiary of Exact Sciences) specializes in rare disease and pediatric genetic diagnostics using whole exome and whole genome sequencing. It is the closest competitor to Variantyx in the rare-disorder/NICU rapid WGS market and overlaps directly on rapid NICU testing products.

TypeDirect peer
Description

Natera is a major molecular diagnostics company offering reproductive genetic testing ( Panorama, Vistara), oncology (Signatera), and rare disease tests. Overlap with Variantyx in reproductive genetics (IriSight) and hereditary cancer (OncoAlly) makes it a comparable specialty molecular diagnostics peer.

TypeDirect peer
Description

Ambry Genetics (part of Tempus AI) provides clinical genetic testing across hereditary cancer, rare disease, reproductive health, and whole genome/exome-based testing. Direct overlap with Variantyx across hereditary cancer panels and rare disorder WES/WGS testing.

TypeDirect peer
Description

Invitae (now operating within Labcorp following acquisition) offers comprehensive genetic testing including whole genome sequencing across rare disease, hereditary cancer, and reproductive health. Direct peer to Variantyx's Genomic Unity and OncoAlly product lines.

TypeDirect peer
Description

Myriad Genetics is an established molecular diagnostics company with strong hereditary cancer and prenatal testing franchises (BRACAnalysis, Foresight, Prequel). It overlaps with Variantyx's OncoAlly hereditary cancer and IriSight reproductive offerings as a competing specialty genetics brand.

TypeBroad incumbent
Description

Quest Diagnostics is a large commercial clinical laboratory offering a broad menu including genetic and genomic testing through its Quest Advanced series and Madison clinic. It is a broader incumbent whose scale and payer relationships compete against Variantyx in hospital and integrated delivery network accounts.

TypeBroad incumbent
Description

Labcorp is a leading global clinical laboratory network with growing specialty genetics capabilities, including via the Invitae acquisition. It competes with Variantyx across rare disease and hereditary cancer testing at scale with deep payer contracts.

TypeEmerging player
Description

Fulgent Genetics offers NGS-based testing across reproductive, oncology, and rare disease genetics with whole genome and exome services. As a smaller, publicly traded specialty molecular diagnostics firm, it is a comparable scale peer competing for similar provider accounts.

TypeEmerging player
Description

PreventionGenetics (now part of Exact Sciences) is a clinical DNA testing lab offering exome and whole genome sequencing for rare disorders. Comparable to Variantyx in the rare-disease and comprehensive WGS segment, though smaller in scale and specialty breadth.

10PerkinElmer Genomics
TypeEmerging player
Description

PerkinElmer Genomics provides clinical whole genome and exome sequencing, carrier screening, and NIPT services. It is a comparable specialty genetics provider that competes with Variantyx in rare-disease diagnostics and reproductive genetics testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Variantyx

Clinical Genetic Diagnostics Servicesvariantyx.com

Variantyx is a private molecular diagnostics company operating a proprietary PCR-free whole genome sequencing platform with Genomic Intelligence software to deliver comprehensive clinical genetic testing for rare disorders, reproductive genetics, oncology, neurology, and wellness applications to healthcare providers across North America and Europe.

What Variantyx does

Variantyx is a private molecular diagnostics company founded in 2014 and headquartered in Framingham, Massachusetts, that provides clinical whole genome sequencing-based genetic testing for rare genetic disorders, reproductive genetics, precision oncology, neurology, and wellness applications. The company operates a proprietary PCR-free whole genome sequencing platform paired with its Genomic Intelligence analytical software, which detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions) from a single sample with reported sensitivity and specificity above 99.9%. Its product portfolio includes the comprehensive Genomic Unity 2.0 test (the only diagnostic combining short-read and long-read sequencing in one report), the Lightning 2.0 rapid genome line delivering results in 5 days or less for NICU/PICU/ICU patients, the OncoAlly hereditary cancer panels, the IriSight reproductive/prenatal testing line, and the Genomic Inform wellness offering, spanning more than 30 distinct SKUs.

Variantyx sells primarily to healthcare providers (geneticists, neurologists, oncologists, obstetricians) through a sales-led go-to-market combining field clinical sales specialists, a Provider Portal for online ordering, and a Clinical Coordination team for fax/phone orders, with mobile phlebotomy coordination and direct-to-patient kit shipping. Tests are billed through commercial insurance, Medicaid, institutional billing, or self-pay, with a Patient Assistance Program available for qualifying commercially insured patients. The company has raised over $125 million in cumulative private financing across multiple rounds since inception, including a $41.5M Series C-2 in February 2022 led by New Era Capital Partners and a $36M round in April 2024 with Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. Operations span North America and Europe, with the 2024 round explicitly funding further technological and commercial expansion as the market shifts from targeted panels and exomes toward whole genome testing.

Variantyx firmographics

Firmographics
Name
Variantyx
Legal name
Variantyx, Inc.
Website
https://variantyx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Variantyx is a private molecular diagnostics company operating a proprietary PCR-free whole genome sequencing platform with Genomic Intelligence software to deliver comprehensive clinical genetic testing for rare disorders, reproductive genetics, oncology, neurology, and wellness applications to healthcare providers across North America and Europe.
Ownership category
akta.pro rank

Variantyx industry classification

Industry
Product category
Clinical Genetic Diagnostics Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Clinical genetic testing
  • Whole genome sequencing
  • Molecular diagnostics
  • Rare disease diagnostics
  • Hereditary cancer testing

Where Variantyx is headquartered

Location

Headquarters

HQ city
Framingham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Variantyx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Genetic Testing Services: Variantyx provides genetic diagnostic testing services to healthcare providers and patients. The company accepts insurance (commercial and Medicaid) and institutional billing, as well as self-pay options. Financial assistance through a Patient Assistance Program is available for patients with commercial insurance meeting certain criteria.
  2. Laboratory Testing: Clinical laboratory testing services billed through insurance or paid directly by patients/providers. Testing includes comprehensive genomic analyses for rare genetic disorders, reproductive genetics, precision oncology, and wellness.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance billing (commercial and Medicaid)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Variantyx product offering

Product offering

Core offering

Variantyx is a clinical molecular diagnostics laboratory providing comprehensive genetic testing services based on PCR-free whole genome sequencing. The company delivers a unified clinical report from a single sample that detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions, methylation patterns), replacing multiple traditional tests such as WES, CMA, MLPA, single-gene panels, and PCR/Southern blot. Test products are organized under the Genomic Unity, OncoAlly, IriSight, Lightning, and Genomic Inform brands and are ordered primarily by healthcare providers for rare disease diagnosis, reproductive genetics, hereditary cancer, and wellness applications.

Product overview

Variantyx is a molecular diagnostics company offering a comprehensive portfolio of genetic testing products built on a proprietary whole genome sequencing (WGS) platform paired with Genomic Intelligence® analytical software. The product ecosystem is organized around two main brands: Genomic Unity® for rare genetic disorders, neurology, reproductive, and precision oncology testing, and OncoAlly® for hereditary cancer analysis. The flagship Genomic Unity® 2.0 combines short and long-read genome sequencing technologies. The comprehensive analysis products (Whole Genome, Exome Plus, Exome Analysis) form the core offering, while targeted analyses cover specific conditions (mitochondrial disorders, cardiomyopathy, ataxia, epilepsy, neuropathies, etc.). Rapid testing is available through the Lightning Genome Analysis line with results in 5 days or less. Reproductive genetics are served through the IriSight® brand for prenatal and pregnancy loss testing. Wellness testing is provided via Genomic Inform®.

Differentiator

Problem solved

Functional benefit

Brands

  • Genomic Unity: Portfolio of tests for rare genetic disorders including whole genome, exome, and targeted analyses
  • OncoAlly
  • IriSight
  • Genomic Inform
  • Lightning
  • Genomic Intelligence

Products and services

  • Genomic Unity® 2.0 The only whole genome-based diagnostic test that combines short and long-read sequencing technologies in one clinical report, identifying genetic variants that correlate with the patient's phenotype. It is the most comprehensive genomic test in the company's portfolio, designed for healthcare providers diagnosing patients with suspected genetic conditions.
  • Genomic Unity® Whole Genome Analysis Comprehensive diagnostic test using a whole genome platform to detect all major clinically relevant variant types from a single sample, replacing WES, CMA, MLPA, and single-gene testing. Ordered by geneticists and other specialists for patients with suspected rare genetic disorders.
  • Genomic Unity® Exome Plus Analysis Comprehensive diagnostic test using the whole genome platform to detect all major clinically relevant variant types from a single sample, analyzing patient DNA jointly with parental DNA when family samples are included. Used by geneticists and other specialists for rare disease diagnosis.
  • Genomic Unity® Lightning Genome Analysis Rapid diagnostic test for acutely ill individuals in NICU, PICU, or ICU settings, providing a comprehensive diagnostic report in 5 days or less using short-read genome sequencing. Lightning 2.0 variants combine short and long-read sequencing with 27-44 repeat expansion gene analysis and methylation analysis for variant phasing.
  • OncoAlly® Comprehensive Hereditary Cancer Analysis Targeted test focusing on 117 genes associated with hereditary cancer, sequencing and analyzing the entire gene for comprehensive variant detection. Used by oncologists and genetic counselors to assess hereditary cancer risk in patients.
  • IriSight® Comprehensive Prenatal Analysis Comprehensive prenatal diagnostic test using the whole genome platform for fetal DNA analysis jointly with parental DNA, replacing WES, CMA, MLPA, and single-gene testing. Ordered by obstetricians, maternal-fetal medicine specialists, and geneticists for pregnancies at elevated risk.
  • Genomic Inform® Wellness Testing Wellness predictive screening test providing information about risks across multiple health areas including cancer, neurological disorders, metabolic disorders, heart conditions, and carrier status. Aimed at healthy adults seeking predictive genetic insights.

Quantifiable outcome

  • 44% diagnostic yield in neonate cases (157 cases), increasing to 48% for classic NICU indications and 71% for select phenotypes
  • +2 more outcomes

Companies that use Variantyx

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Variantyx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Variantyx partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Variantyx competitors and assessment

Company assessment

Direct peers

  • GeneDx: GeneDx (a subsidiary of Exact Sciences) specializes in rare disease and pediatric genetic diagnostics using whole exome and whole genome sequencing. It is the closest competitor to Variantyx in the rare-disorder/NICU rapid WGS market and overlaps directly on rapid NICU testing products.
  • Natera: Natera is a major molecular diagnostics company offering reproductive genetic testing ( Panorama, Vistara), oncology (Signatera), and rare disease tests. Overlap with Variantyx in reproductive genetics (IriSight) and hereditary cancer (OncoAlly) makes it a comparable specialty molecular diagnostics peer.
  • Ambry Genetics: Ambry Genetics (part of Tempus AI) provides clinical genetic testing across hereditary cancer, rare disease, reproductive health, and whole genome/exome-based testing. Direct overlap with Variantyx across hereditary cancer panels and rare disorder WES/WGS testing.
  • Invitae: Invitae (now operating within Labcorp following acquisition) offers comprehensive genetic testing including whole genome sequencing across rare disease, hereditary cancer, and reproductive health. Direct peer to Variantyx's Genomic Unity and OncoAlly product lines.
  • Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with strong hereditary cancer and prenatal testing franchises (BRACAnalysis, Foresight, Prequel). It overlaps with Variantyx's OncoAlly hereditary cancer and IriSight reproductive offerings as a competing specialty genetics brand.

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is a large commercial clinical laboratory offering a broad menu including genetic and genomic testing through its Quest Advanced series and Madison clinic. It is a broader incumbent whose scale and payer relationships compete against Variantyx in hospital and integrated delivery network accounts.
  • Labcorp: Labcorp is a leading global clinical laboratory network with growing specialty genetics capabilities, including via the Invitae acquisition. It competes with Variantyx across rare disease and hereditary cancer testing at scale with deep payer contracts.

Emerging players

  • Fulgent Genetics: Fulgent Genetics offers NGS-based testing across reproductive, oncology, and rare disease genetics with whole genome and exome services. As a smaller, publicly traded specialty molecular diagnostics firm, it is a comparable scale peer competing for similar provider accounts.
  • PreventionGenetics: PreventionGenetics (now part of Exact Sciences) is a clinical DNA testing lab offering exome and whole genome sequencing for rare disorders. Comparable to Variantyx in the rare-disease and comprehensive WGS segment, though smaller in scale and specialty breadth.
  • PerkinElmer Genomics: PerkinElmer Genomics provides clinical whole genome and exome sequencing, carrier screening, and NIPT services. It is a comparable specialty genetics provider that competes with Variantyx in rare-disease diagnostics and reproductive genetics testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Variantyx social profiles

Digital presence

Variantyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Variantyx leadership team

Management profile

Number of profiles

Profiles7 records

Variantyx funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Variantyx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Variantyx

What does Variantyx do?

Variantyx is a clinical molecular diagnostics laboratory providing comprehensive genetic testing services based on PCR-free whole genome sequencing. The company delivers a unified clinical report from a single sample that detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions, methylation patterns), replacing multiple traditional tests such as WES, CMA, MLPA, single-gene panels, and PCR/Southern blot. Test products are organized under the Genomic Unity, OncoAlly, IriSight, Lightning, and Genomic Inform brands and are ordered primarily by healthcare providers for rare disease diagnosis, reproductive genetics, hereditary cancer, and wellness applications.

Is Variantyx a public or private company?

Variantyx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Variantyx founded?

Variantyx was founded in 2014. It employs 101 to 250 people.

Where is Variantyx based?

Variantyx is headquartered in Framingham, United States, in the North America region.

How does Variantyx make money?

Two revenue lines are on record. Genetic Testing Services are the primary driver. The others are laboratory Testing.

Who are Variantyx's main competitors?

Direct peers on record are GeneDx, Natera, Ambry Genetics, Invitae and Myriad Genetics. Broad incumbents are Quest Diagnostics and Labcorp. Emerging players are Fulgent Genetics, PreventionGenetics and PerkinElmer Genomics.

Does Variantyx have an API?

No public API is recorded for Variantyx.

What industry is Variantyx in?

Variantyx's product category is Clinical Genetic Diagnostics Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
F6s66 Top Genomics Companies in United States · December 2025The article presents a directory of 66 top genomics companies and startups operating in the United States as of December 2025, sourced from the F6S community. It highlights various entities involved in precision medicine, diagnostics, bioinformatics, and data storage, such as Variantyx, Invitae Corporation, and 10X Genomics. The list serves as an industry snapshot for the healthcare and biotechnology sectors.Business Wire BlogVariantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0Variantyx launched Genomic Unity 2.0, a whole genome diagnostic test combining short- and long-read sequencing. It detects variants missed by other methods, offers methylation status and variant phasing, and claims to identify over 44 repeat expansions.FinSMEsVariantyx Raises $36M in FundingVariantyx, a Framingham, MA-based molecular diagnostics company, raised $36M in funding from backers including Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. The round brings total investment to over $125M, which the company will use for technological and commercial expansion to provide genome-based care to more patients.Pulse 2.0Variantyx: Molecular Diagnostics Company Closes $36 Million In FundingMolecular diagnostics company Variantyx secured $36 million in additional funding from investors including Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. This investment brings the company's total capital raised to over $125 million, which will be used to fund technological and commercial expansion to meet growing market demand for whole genome testing.TmcnetVariantyx Secures $36M Investment As Testing Demand And Market Share Continues To IncreaseVariantyx secured $36 million in additional funding from its portfolio of investors, bringing total investment to over $125 million. The company reported rapid test volume growth in Q1 2024, expanding its market share. The funds will support technological and commercial expansion.Pulse 2.0Variantyx: Genomic Precision Medicine Company To Expand With New Funding RoundVariantyx, a genomic precision medicine company, secured additional funding from its portfolio of investors, including Robert Bosch Venture Capital and Pitango HealthTech. The round brings total investment to over $120 million, to drive commercial expansion and build economic value. The company continues to add major US healthcare systems to its customer base.FinSMEsVariantyx Raises Additional FundingVariantyx, a Framingham, MA-based genomic precision medicine company, raised an undisclosed additional funding round. The funds, bringing total funding to over $120m, will accelerate its commercial expansion. The company, led by CEO Haim Neerman, provides whole genome analysis platforms for genetic disorders, reproductive health, and precision oncology.YahooVariantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial FootprintVariantyx announced additional funding from its portfolio of investors, including Robert Bosch Venture Capital and others. The investment brings total funding to over $120 million, fueling commercial expansion. The company aims to expand its customer base and bring precision medicine to more patients.VC News DailyVariantyx Announces Additional InvestmentVariantyx announced it has secured additional funding from its existing investors, bringing the company's total investment to over $120 million. The capital will be used to fuel commercial expansion and accelerate the deployment of its genomic precision medicine services. This move supports Variantyx's ongoing growth in adding US healthcare systems to its customer base.